Skip to main content Back to Top
Advertisement

5/17/2016

Methylphenidate Hydrochloride Extended Release Oral Presentations

Products Affected - Description

    • Methylphenidate LA extended release capsule, Actavis, 20 mg, 100 count, NDC 67767-0200-01
    • Methylphenidate LA extended release capsule, Actavis, 30 mg, 100 count, NDC 67767-0201-01
    • Methylphenidate LA extended release capsule, Actavis, 40 mg, 100 count, NDC 67767-0202-01
    • Methylphenidate LA extended release capsule, Teva, 20 mg, 100 count, NDC 00093-5346-01
    • Methylphenidate LA extended release capsule, Teva, 30 mg, 100 count, NDC 00093-5347-01
    • Methylphenidate LA extended release capsule, Teva, 40 mg, 100 count, NDC 00093-5348-01

Reason for the Shortage

    • Actavis states the shortage of methylphenidate was due to increased demand. Actavis discontinued methylphenidate LA 30 mg and 40 mg tablets in late-2015.
    • Janssen states the shortage of Concerta was due to increased demand.
    • Kremers Urban had Methylphenidate CD on allocation due to increased demand.
    • Mallinckrodt states the shortage was due to delay in obtaining raw materials.
    • Novartis discontinued Ritalin SR in October 2014.
    • Teva introduced generic methylphenidate extended release capsules (CD) in late-September 2012, and these capsules are AB-rated to Metadate CD capsules.
    • UCB states methylphenidate ER tablets were on shortage due to supply and demand.

Available Products

    • Concerta extended release tablet, Janssen, 18 mg, 100 count, NDC 50458-0585-01
    • Concerta extended release tablet, Janssen, 27 mg, 100 count, NDC 50458-0588-01
    • Concerta extended release tablet, Janssen, 36 mg, 100 count, NDC 50458-0586-01
    • Concerta extended release tablet, Janssen, 54 mg, 100 count, NDC 50458-0587-01
    • Metadate CD extended release capsule, UCB, 10 mg, 100 count, NDC 53014-0579-07
    • Metadate CD extended release capsule, UCB, 20 mg, 100 count, NDC 53014-0580-07
    • Metadate CD extended release capsule, UCB, 30 mg, 100 count, NDC 53014-0581-07
    • Metadate CD extended release capsule, UCB, 40 mg, 100 count, NDC 53014-0582-07
    • Metadate CD extended release capsule, UCB, 50 mg, 100 count, NDC 53014-0583-07
    • Metadate CD extended release capsule, UCB, 60 mg, 100 count, NDC 53014-0584-07
    • Metadate ER extended release tablet, UCB, 20 mg, 100 count, NDC 53014-0594-01
    • Metadate ER extended release tablet, UCB, 20 mg, 100 count, NDC 53014-0594-07
    • Methylphenidate CD extended release capsule, Kremers Urban, 10 mg, 100 count, NDC 62175-0151-37
    • Methylphenidate CD extended release capsule, Kremers Urban, 20 mg, 100 count, NDC 62175-0152-37
    • Methylphenidate CD extended release capsule, Kremers Urban, 30 mg, 100 count, NDC 62175-0153-37
    • Methylphenidate CD extended release capsule, Kremers Urban, 40 mg, 100 count, NDC 62175-0154-37
    • Methylphenidate CD extended release capsule, Kremers Urban, 50 mg, 100 count, NDC 62175-0155-37
    • Methylphenidate CD extended release capsule, Kremers Urban, 60 mg, 100 count, NDC 62175-0156-37
    • Methylphenidate CD extended release capsule, Teva, 10 mg, 100 count, NDC 00093-5295-01
    • Methylphenidate CD extended release capsule, Teva, 20 mg, 100 count, NDC 00093-5296-01
    • Methylphenidate CD extended release capsule, Teva, 30 mg, 100 count, NDC 00093-5297-01
    • Methylphenidate CD extended release capsule, Teva, 40 mg, 100 count, NDC 00093-5298-01
    • Methylphenidate CD extended release capsule, Teva, 60 mg, 100 count, NDC 00093-5293-01
    • Methylphenidate CD extended release capsule, Teva, 50 mg 100 count, NDC 00093-5292-01
    • Methylphenidate LA extended release capsule, Actavis, 20 mg, 100 count, NDC 45963-0200-11
    • Ritalin LA extended release capsule, Novartis, 10 mg, 100 count, NDC 00078-0424-05
    • Ritalin LA extended release capsule, Novartis, 20 mg, 100 count, NDC 00078-0370-05
    • Ritalin LA extended release capsule, Novartis, 30 mg, 100 count, NDC 00078-0371-05
    • Ritalin LA extended release capsule, Novartis, 40 mg, 100 count, NDC 00078-0372-05
    • Ritalin LA extended release capsule, Novartis, 60 mg, 100 count, NDC 00078-0658-15
    • Methylphenidate Hydrochloride extended release tablet, Actavis, 18 mg, 100 count, NDC 00591-2715-01
    • Methylphenidate Hydrochloride extended release tablet, Actavis, 27 mg, 100 count, NDC 00591-2716-01
    • Methylphenidate Hydrochloride extended release tablet, Actavis, 36 mg, 100 count, NDC 00591-2717-01
    • Methylphenidate Hydrochloride extended release tablet, Actavis, 54 mg, 100 count, NDC 00591-2718-01
    • Methylphenidate Hydrochloride extended release tablet, Kremers Urban, 18 mg, 100 count, NDC 62175-0310-37
    • Methylphenidate Hydrochloride extended release tablet, Kremers Urban, 27 mg, 100 count, NDC 62175-0311-37
    • Methylphenidate Hydrochloride extended release tablet, Kremers Urban, 36 mg, 100 count, NDC 62175-0312-37
    • Methylphenidate Hydrochloride extended release tablet, Kremers Urban, 54 mg, 100 count, NDC 62175-0313-37
    • Methylphenidate Hydrochloride extended release tablet, Mallinckrodt, 10 mg, 100 count, NDC 00406-1445-01
    • Methylphenidate Hydrochloride extended release tablet, Mallinckrodt, 20 mg, 100 count, NDC 00406-1473-01
    • Methylphenidate Hydrochloride extended release tablet, Mallinckrodt, 27 mg, 100 count, NDC 00406-0127-01
    • Methylphenidate Hydrochloride extended release tablet, Mallinckrodt, 36 mg, 100 count, NDC 00406-0136-01
    • Methylphenidate Hydrochloride extended release tablet, Mallinckrodt, 54 mg, 100 count, NDC 00406-0154-01

Estimated Resupply Dates

    • Teva has all methylphenidate LA extended release capsules on temporarily unavailable and the company cannot estimate when product will return.

Updated

Updated May 17, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 8, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT